Abstract：Under the guidance of our previous achievements, and in order to extend this small molecular library. In current work, other 21 novel structures of 
Introduction
Cancer is the leading cause of death after cardiovascular disease, and the relative mortality rate caused by cancer is still very high even in developed countries, statically evident around 6-7 million new cases per year [1] . Lung cancer is the number one cause of cancer related death globally, with an estimated 13% of total cases and accounting for 18% of total deaths worldwide in 2008 [2] . In 2010, there were 222,520 new lung cancer patients diagnosed and 157,300 died [3] . However, the non-small cell lung cancer (NSCLC) is usually diagnosed in advanced stages and accounts for 85% of all lung cancer diagnoses in the United States [4] . In China, it is reported that lung cancer has replaced the liver cancer as the number one cause of death among people with malignant tumors in 2008 [5] .
Breast cancer is also the most common cancer among American women. It was reported that one in every eight women in the United States was found to have breast cancer. According to American Cancer Society, nearly 40,000 women had died of breast cancer in 2011, and about 232,340 new cases of invasive breast cancer will be diagnosed each year. Thus, cancer has been a great threat to human survival, which prompts us to search for new drugs for treatment of cancer. Furthermore, we evaluated their biological activity against lung cancer cell line A549, colorectal cancer cell line HCT116 and breast cancer cell line MCF-7.
Results and discussion

Chemistry
To obtain more potent anticancer agent as well as to study their structure-activity relationship (SAR), different substitution patterns at the 6-position of the thieno [2,3-d] pyrimidine core and on the benzene ring of isxoazole moiety were selected based on the substutition's volume and electronic environments, which would affect lipophilicity and steric hindrance, and hence the anticancer activity of the target molecules. Based on these factors, 21 novel structures of thieno [2,3-d] pyrimidine derivatives containing isoxazole-moiety were synthesized and characterized by 1 H NMR, 13 C NMR, IR and mass spectrometry. Their in vitro anticancer activity against lung cancer A549, colorectal cancer HCT116 and breast cancer MCF-7 cell lines was preliminarily evaluated.
Analytical spectral data of compounds 3a-u
The IR spectral data of compounds 3a-u showed a characteristic absorption band at the 3103-3107 cm -1 , which corresponds to the thiophene core, =C-H and Ph-H. The absorption band of the aromatic cycle skeleton, N=C group and the stretching frequency of C=C showed an absorption band at 1548-1567 cm 
In vitro anticancer evaluation
We preliminarily evaluated the synthesized compounds 3a-u for in vitro anticancer activity against A549, HCT116 and MCF-7 cell lines. The anticancer efficacy was comparable to the standard drug (gefitinib) ( Table 1) . It can be seen from the Table 1 , the half of compounds exhibit good to excellent anticancer activity 8 against A549, HCT116 and MCF-7 cell lines. For 3a-g, it indicates that introducing the methyl and methoxy group to 4-position of the benzene ring of the isoxazole mioety will reduce their anticancer activity (For example, 3a is the most potent compounds among 3a-c, and the active sequence is 3a>3b>3c); while for 3d-g, it indicates that introducing the halogen atom to 4-position of the benzene ring of the isoxazole moiety will increase their anticancer activity, and 4-Cl substituted derivative is more potent than 4-Br substituted derivative; 3e is the most potent compound among 3a-g. In fact, 3e is 6.4-fold more active than gefitinib against A549, 3.2-fold more active than gefitinib against HCT116 and 4912-fold much more active than gefitinib against MCF-7. For 3h-n (6-position of thieno [2,3-d] pyrimidine core is substituted by ethyl group), the anticancer activity of these compounds exhibited the same trend observed for compounds 3a-g. However, compounds 3j and 3k exhibited much stronger inhibition against A549 cell line and are the most potent ones among 3h-n. Substance 3j (IC50 =5.50×10 -4 μM) is 32545-fold more active than gefitinib (IC50 = 17.90 μM) against A549 cell line; while 3k (IC50 = 7.14×10 -3 μM) is 2507-fold more active than gefitinib (IC50 = 17.90 μM) against A549 cell line. Furthermore, 3j and 3k also exhibited potent anticancer activity against HCT116 cell line. For 3o-u (6-position of thieno [2,3-d] pyrimidine core is substituted by tert-butyl group), as evidence from Table 1 , the anticancer activity against A549 and HCT116 cell lines of these compounds is not remarkable, but the anticancer activity against MCF-7 is: 3o Compounds 3a, 3e, 3g and 3h exhibited a broad-spectrum and much stronger inhibitory activity against these tumor cell lines, for which they are considered promising drug candidates for development of anticancer drugs.
Experimental
Materials and apparatus
Melting points ( o C, uncorrected) were determined on a XT5 micrio melting point apparatus. NMR spectra were recorded on Bruker AVANCE III at 400 MHz for 1 H and 100 MHz for 13 C, using TMS as internal standard and peak multiplicities was designed as follows: singlet (s), doublet (d), triplet (t), quartet (q) and multiplet (m).
The coupling constants, J, are reported in Hertz (Hz). The FTIR spectra were recorded on VERTEX70, in KBr discs in the 600-3600 cm penicillin-streptomycin were purchased from Invitrogen. The intermediates
according to our reported procedures [61] . Other chemicals were commercially available, and used without further purification. Isopropyl alcohol (iso-PrOH) was dried over anhydrous magnesium sulfate before use.
General procedure for the preparation of the target compounds 3a-u
General synthesis of 3a:
(0.184 g, 1 mmol) was added into a 25 mL one-necked round-bottom flask with 5mL
of dry iso-PrOH, and the mixture was stirred in a cold bath. Then a solution of Et3N (0.101 g, 1 mmol) and (3-phenyl-isoxazole-5-yl)-methanol (0.175 g, 1 mmol) in 10mL dry iso-PrOH was slowly added to the reaction system using a syringe. The mixture was stirred in a cold bath for an additional 30 min, and then temperature was allowed to reach room temperature. After reaction completion (monitored by thin layer chromatography, TLC), the reaction mixture was evaporated under reduced The mixture of DMSO, PBS and DMEM was used as a negative control and Gefitinib was used as the reference drug. The detailed process was reported earlier [34, 35, 60] .
6-Methyl-4-[(3-p-tolyl-isoxazol-5-yl-)methoxy]-thieno[2,3-d]pyrimidine(3b)
6-Methyl-4-{[3-(4-methoxyphenyl)-isoxazol-5-yl-]-methoxy-}-thieno[2,3-d]pyrimidine (3c)
6-Ethyl-4-[(3-phenyl-isoxazol-5-yl-)-methoxy-]-
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6-Ethyl-4-{[3-(4-methoxyphenyl)-isoxazol-5-yl-]-methoxy-}-thieno[2,3-d]pyrimidine (3j)
6-Ethyl-4-{[3-(2-chlorophenyl)-isoxazol-5-yl-]-methoxy}-thieno[2,3-d]pyrimidine (3k)
6-Ethyl-4-{[3-(4-chlorophenyl)-isoxazol-5-yl-]-methoxy}-
6-Ethly-4-{[3-(4-bromophenyl)-isoxazol-5-yl-]-methoxy}-thieno[2,3-d]pyrimidine (3n)
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